Login
$LTRN
$0.39 +$0.00 (0.64%) After hours

$LTRN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
21 Oct 2026 ARS
19 Oct 2026 DEF 14A
13 Oct 2026 SCHEDULE 13G/A
08 Oct 2026 PRE 14A
01 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On September 25, 2026, Lantern Pharma Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of lis...

30 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2026, between Lantern Pharma Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it...

30 Sep 2026 424B5
24 Sep 2026 8-K: Regulation FD Disclosure

On September 23, 2026, Lantern Pharma Inc. (the “Company”) hosted a live webinar to discuss the Open-Medicine AI multi-agentic AI platform for drug development.

23 Sep 2026 8-K: Regulation FD Disclosure

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

14 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

14 Aug 2026 10-Q
04 Aug 2026 SCHEDULE 13G
03 Aug 2026 8-K: Regulation FD Disclosure

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

23 Jul 2026 SCHEDULE 13G/A
18 Jun 2026 EFFECT
12 Jun 2026 S-1
02 Jun 2026 8-K: Regulation FD Disclosure

On June 1, 2026, Lantern Pharma Inc. (the “Company”) utilized a presentation to assist with the Company’s discussions regarding the Harmonic™ Phase 2 clinical trial for the Company’s product candidate known as LP-300.

21 May 2026 D
15 May 2026 SCHEDULE 13D/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support